Search research articles
Contact Us
Filters
Showing results (61-70 of 72) with videos related to
Page
of 8
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
December 16, 2017
Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial
Peter S Hall, Alison Smith, Claire Hulme, et al.
The Lancet. Oncology
|
May 16, 2015
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial
Helena M Earl, Louise Hiller, Janet A Dunn, et al.
The Lancet. Oncology
|
December 24, 2013
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial
Helena M Earl, Anne-Laure Vallier, Louise Hiller, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
May 27, 2017
Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial
Jeremy St John Thomas, Elena Provenzano, Louise Hiller, et al.
Journal of the National Cancer Institute
|
May 1, 2016
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others
John M S Bartlett, Jane Bayani, Andrea Marshall, et al.
Health Technology Assessment (Winchester, England)
|
September 4, 2020
Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT
Helena Earl, Louise Hiller, Anne-Laure Vallier, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society
|
July 20, 2017
Aiming for a holistic integrated service for men diagnosed with prostate cancer - Definitions of standards and skill sets for nurses and allied healthcare professionals
Alastair D Lamb, Sue Thompson, Netty Kinsella, et al.
Cell
|
December 4, 2003
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
Luke Hughes-Davies, David Huntsman, Margarida Ruas, et al.
Lancet (London, England)
|
June 11, 2019
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
Helena M Earl, Louise Hiller, Anne-Laure Vallier, et al.
Bone & Joint Open
|
February 12, 2024
Radiological outcomes following surgical fixation with wires versus moulded cast for patients with a dorsally displaced fracture of the distal radius: a radiographic analysis from the DRAFFT2 trial
Caroline E Plant, Alexander Ooms, Jonathan A Cook, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 72) with videos related to
Sort By:
Page
of 8
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
December 16, 2017
Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial
Peter S Hall, Alison Smith, Claire Hulme, et al.
The Lancet. Oncology
|
May 16, 2015
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial
Helena M Earl, Louise Hiller, Janet A Dunn, et al.
The Lancet. Oncology
|
December 24, 2013
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial
Helena M Earl, Anne-Laure Vallier, Louise Hiller, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
May 27, 2017
Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial
Jeremy St John Thomas, Elena Provenzano, Louise Hiller, et al.
Journal of the National Cancer Institute
|
May 1, 2016
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others
John M S Bartlett, Jane Bayani, Andrea Marshall, et al.
Health Technology Assessment (Winchester, England)
|
September 4, 2020
Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT
Helena Earl, Louise Hiller, Anne-Laure Vallier, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society
|
July 20, 2017
Aiming for a holistic integrated service for men diagnosed with prostate cancer - Definitions of standards and skill sets for nurses and allied healthcare professionals
Alastair D Lamb, Sue Thompson, Netty Kinsella, et al.
Cell
|
December 4, 2003
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
Luke Hughes-Davies, David Huntsman, Margarida Ruas, et al.
Lancet (London, England)
|
June 11, 2019
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
Helena M Earl, Louise Hiller, Anne-Laure Vallier, et al.
Bone & Joint Open
|
February 12, 2024
Radiological outcomes following surgical fixation with wires versus moulded cast for patients with a dorsally displaced fracture of the distal radius: a radiographic analysis from the DRAFFT2 trial
Caroline E Plant, Alexander Ooms, Jonathan A Cook, et al.
Page
of 8